Submit to Biomedicines Review for Biomedicines Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 8795

Share This Special Issue

Special Issue Editor

Prof. Dr. Shaker A. Mousa

E-Mail Website
Guest Editor

1. The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY 12144, USA
2. Vascular Vision Pharmaceuticals Co., Rensselaer Polytechnic Park, Troy, NY 12180 USA
Interests: pharmaceuticals; biopharmaceuticals and diagnostics; nanomedicine; cardiovascular diseases; neurological disorders; hematology and oncology; biosimilar and nanosimilar; angiogenesis; inflammation; thrombosis; integrin and cell adhesion molecules; target identification; molecular mechanisms and signaling pathways; preclinical; clinical; marketing and post marketing studies; regulatory and ethical issues
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Evidence from the scientific and medical communities has demonstrated the potential impact of nanotechnology/biotechnology and nanomedicine on the improved management of cancer and other disorders, in terms of early diagnosis and targeted therapy, leading to significant progress in accelerating precision medicine applications. The utilization of nanobiotechnology for the development of novel targeted nanocarrier systems has the potential to offer improved biomedicine (small molecule, peptide, and genes) delivery through improved pharmacokinetics, pharmacodynamics, and safety profiles. Targeted delivery of drug-incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands, could enhance the efficacy and safety of anticancer drugs. Additionally, multifunctional characteristics of the nanocarrier system would allow for simultaneous imaging of various types of cancers/microenvironments and targeted drug delivery (therapeutics) along with monitoring (theranostics).

The scope of this Special Issue is to cover recent progress in nanotechnology/biotechnology as it relates to nanomedicine, targeted delivery of medicines and biomedicines, and diagnostics. A key aim is to present the latest advances in various nanomedicine approaches for the detection and treatment of various types of organ-specific diseases, vascular targeting, vaccine development, and the overall impact of nanomedicine on advancing precision medicine. Additionally, this Special Issue aims to cover nanonutraceuticals, nanocosmetics using a single or a combination of various bioactive compounds derived from natural products, and impacts on disease prevention.

Prof. Dr. Shaker Mousa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

nanotechnology
biotechnology
nanomedicines
biomedicines
precision medicine
nano-pharmaceuticals
nano-nutraceuticals
nano-cosmetics
imaging
diagnostics
theranostics
disease prevention
treatment
early detection

Related Special Issue:

Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine in Biomedicines (7 articles)

Published Papers (5 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Other

Open AccessArticle

The Neuroprotective and Antioxidant Effects of Nanocurcumin Oral Suspension against Lipopolysaccharide-Induced Cortical Neurotoxicity in Rats

and

Biomedicines 2022, 10(12), 3087; https://doi.org/10.3390/biomedicines10123087 - 01 Dec 2022

Viewed by 1132

Abstract

Lipopolysaccharide (LPS) proved to be an important tool, not only in the induction of neuroinflammatory models, but also in demonstrating the behavioral and cognitive consequences of endotoxemia. Curcumin, in its native form, has proven to be a worthy candidate for further development as it protects the dopaminergic neurons against LPS-induced neurotoxicity. However, it remains hindered by its poor bioavailability. In this study we aim to explore the possible molecular mechanism of LPS-induced neurotoxicity and the possible protective effects of orally supplemented nanocurcumin. Thirty-six adult male Wistar rats weighing 170–175 g were divided into six groups and treated with single I.P. (intra-peritoneal) dose of LPS (sigma and extracted; separately) (5 mg/kg BW) plus daily oral nanocurcumin (15 mg/kg BW). The rats were followed for 7 days after the LPS injection and nanocurcumin supplementations daily via oral gavage. After scarification, the levels of neurotransmitters, antioxidants, and amyloidogenesis markers were assessed in brain tissues. Nanocurcumin showed adequate antioxidant and neuroprotective effects, rescuing the rats which had been injected intraperitoneally with LPS endotoxin. Full article

(This article belongs to the Special Issue Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0)

► Show Figures

Figure 1

Open AccessArticle

Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult

Ozlem Ozen Karakus

Noureldien H. E. Darwish

Thangirala Sudha

Taher A. Salaheldin

Kazutoshi Fujioka

Peter C. Taylor Dickinson

Brian Weil

and

Shaker A. Mousa

Biomedicines 2021, 9(11), 1713; https://doi.org/10.3390/biomedicines9111713 - 18 Nov 2021

Cited by 3 | Viewed by 1593 | Correction

Abstract

Ischemic heart disease is the main cause of death globally. Cardioprotection is the process whereby mechanisms that reduce myocardial damage, and activate protective factors, contribute to the preservation of the heart. Targeting these processes could be a new strategy in the treatment of post-ischemic heart failure (HF). Triiodothyronine (T3) and thyroxine (T4), which have multiple effects on the heart, prevent myocardial damage. This study describes the formulation, and characterization, of chemically modified polymeric nanoparticles incorporating T3, to target the thyroid hormone receptors. Modified T3 was conjugated to polylactide-co-glycolide (PLGA) to facilitate T3 delivery and restrict its nuclear translocation. Modified T3 and PLGA-T3 was characterized with ¹H-NMR. The protective role of synthesized phosphocreatine (PCr) encapsulated PLGA-T3 nanoparticles (PLGA-T3/PCr NPs) and PLGA-T3 nanoparticles (PLGA-T3 NPs) in hypoxia-mediated cardiac cell insults was investigated. The results showed that PLGA-T3/PCr NPs represent a potentially new therapeutic agent for the control of tissue damage in cardiac ischemia and resuscitation. Full article

(This article belongs to the Special Issue Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0)

► Show Figures

Graphical abstract

Open AccessArticle

Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer

Ali H. El-Far

Kavitha Godugu

Taher A. Salaheldin

Noureldien H. E. Darwish

Amna A. Saddiq

and

Shaker A. Mousa

Biomedicines 2021, 9(8), 990; https://doi.org/10.3390/biomedicines9080990 - 10 Aug 2021

Cited by 8 | Viewed by 2439

Abstract

Costunolide (COS) is a sesquiterpene lactone with anticancer properties. The present study investigated the anticancer effects of COS against the human colon (HCT116) and breast (MDA-MB-231-Luc) cancer cell lines. Inhibition of cell lines viability and IC50 of COS were assessed via an MTT assay. Furthermore, the apoptotic rate was detected by assessment of Bcl2-associated X (Bax) and B-cell lymphoma 2 (Bcl2) protein levels by flow cytometry. Xenograft mice model of HCT116 and MDA-MB-231-Luc were carried out to determine the effect of COS and its nanoparticles (COS-NPs). The results demonstrated that COS inhibited the viability of HCT116 and MDA-MB-231-Luc cells, with a half maximal inhibitory concentration value (IC50) of 39.92 µM and 100.57 µM, respectively. COS significantly increased Bax and decreased Bcl2 levels in treated cells. COS and COS-NPs, in combination with doxorubicin (DOX), significantly decreased the tumor growth of HCT116 and MDA-MB-231-Luc implants in mice. Furthermore, oral administration of COS and COS-NPs significantly decreased the viable cells and increased necrotic/apoptotic cells of HCT116 and MDA-MB-231-Luc implants. Interestingly, both COS and COS-NPs protected the cardiac muscles against DOX’s cardiotoxicity. The current results indicated the promising anticancer and cardiac muscles protection of COS and COS-NPs when administered with chemotherapy. Full article

(This article belongs to the Special Issue Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0)

► Show Figures

Figure 1

Open AccessArticle

Tethered Lipid Membranes as a Nanoscale Arrangement towards Non-Invasive Analysis of Acute Pancreatitis

and

Biomedicines 2021, 9(7), 755; https://doi.org/10.3390/biomedicines9070755 - 29 Jun 2021

Cited by 3 | Viewed by 1757

Abstract

Extracellular heat shock proteins (HSPs) mediate immunological functions and are involved in pathologies such as infection, stress, and cancer. Here, we demonstrated the dependence of an amount of HSP70 and HSP90 in serum vs. severity of acute pancreatitis (AP) on a cohort of 49 patients. Tethered bilayer lipid membranes (tBLMs) have been developed to investigate HSPs’ interactions with tBLMs that can be probed by electrochemical impedance spectroscopy (EIS). The results revealed that HSP70 and HSP90 interact via different mechanisms. HSP70 shows the damage of the membrane, while HSP90 increases the insulation properties of tBLM. These findings provide evidence that EIS offers a novel approach for the study of the changes in membrane integrity induced by HSPs proteins. Herein, we present an alternative electrochemical technique, without any immunoprobes, that allows for the monitoring of HSPs on nanoscaled tBLM arrangement in biologics samples such us human urine. This study demonstrates the great potential of tBLM to be used as a membrane based biosensor for novel, simple, and non-invasive label-free analytical system for the prediction of AP severity. Full article

(This article belongs to the Special Issue Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0)

► Show Figures